Home › Amgen says Kyprolis doubles progression-free survival vs Velcade
 

Keywords :   


Amgen says Kyprolis doubles progression-free survival vs Velcade

2015-03-02 04:09:37| Biotech - Topix.net

Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. REUTERS: Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

Tags: survival doubles amgen progressionfree survival

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05Valmet Names New Vice President Services, North America
20.05NABC hosts foreign animal disease tabletop exercise
20.05NABC hosts foreign animal disease tabletop exercise
More »